长链非编码RNA参与扩张型心肌病发生发展机制的研究进展

Research progress of long non⁃coding RNA in dilated cardiomyopathy

扩张型心肌病(DCM)是以左室、右室或双心腔扩大和舒缩功能障碍为主要特征的复合型心肌病,具有高发病率、高死亡率、逐渐年轻化等特点。DCM可引起心律失常、严重心力衰竭,甚至猝死,但目前尚缺乏有效的治疗方案,PCM病死率居高不下,是心血管系统疾病一大治疗难题。长链非编码RNA(lncRNAs)不参与或很少参与蛋白质编码,研究发现,lncRNAs在DCM发生发展过程中扮演着重要角色。为寻求更好的治疗方案,目前DCM研究热点转向基因分子水平,探索相关临床诊断标志物和治疗靶点。本文就lncRNAs参与调控DCM作用机制及研究进展进行综述,旨在为DCM的预防和治疗提供新的方向。

Dilated cardiomyopathy is a type of composite cardiomyopathy characterized by left ventricular,right ventricu‐lar or double ventricular enlargement and diastolic dysfunction,with high incidence,high mortality and gradually getting younger.With the progressive development of the disease,it can cause arrhythmia,severe heart failure,thromboembolism,and even sud‐den death.Currently,there is no effective treatment plan,and the high mortality rate is a major problem in the treatment of cardio‐vascular diseases.Long‐chain non‐coding RNAs(lncRNAs)are a class of RNAs with a molecular mass of more than 200 bt and which are not involved or rarely involved in protein coding.Studies have shown that lncRNAs play an important role in the occur‐rence and development of dilated cardiomyopathy.Finding relevant clinical diagnostic markers and therapeutic targets is the current research focus in the field of dilated cardiomyopathy.This article reviews the mechanism and research progress of lncRNAs in the occurrence and development of dilated cardiomyopathy,and aims to provide a new direction for the prevention and treatment of di‐lated cardiomyopathy.